- Home
- RLAY vs PTA Comparison
RLAY vs PTA Comparison
Compare RLAY & PTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLAY | PTA |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLAY | PTA |
|---|---|---|
| Price | $9.15 | $19.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $15.75 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 159.2K |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,355,000.00 | N/A |
| Revenue This Year | $19.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.78 | $15.84 |
| 52 Week High | $9.25 | $19.67 |
Technical Indicators
Market Signals| Indicator | RLAY | PTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 50.72 |
| Support Level | $8.08 | $19.60 |
| Resistance Level | $9.25 | $19.86 |
| Average True Range (ATR) | 0.67 | 0.15 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 83.02 | 38.89 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.